INTRODUCTION: Psoriasis is a chronic, immune-mediated inflammatory skin disease. Despite the availability of several therapies, many patients affected by this disease remain untreated, do not have adequate response, or suffer from treatment-related toxic effects. It has been shown that the interleukin (IL)-17 pathway plays a key role in the immunopathogenesis of psoriasis. Brodalumab, the first human monoclonal IgG2 antibody that selectively binds to subunit A of the human IL-17 receptor, blocking interactions with a number of cytokines of the IL-17 family, has confirmed fast onset of action, high complete clearance rates, and sustained efficacy. Nevertheless, there is only a limited amount of published real-world evidence (RWE) data. METHODS: This was an open-label, multicenter, real-world, prospective, non-interventional, non-controlled (single-arm) observational study (LIBERO-CZ) assessing the management of moderate to severe psoriasis with brodalumab in daily practice for up to 52 weeks of treatment. RESULTS: Fifty-four patients (70.4% male, mean age 46.9 ± 13.4 years, weight 95.6 ± 22.7 kg, disease duration 18.6 ± 12.7 years) were enrolled and included in the final analysis. Forty-nine of the patients completed the study and five discontinued prematurely; 51.8% of all the enrolled patients were biologic-naïve. At baseline, 28% patients were classified as severe (psoriasis area severity index (PASI) ≥ 20). Overall, the mean PASI decreased by 15.6 from 16.1 (± 5.0) at baseline to 0.5 (± 1.2) at the last visit. The primary endpoint of an absolute PASI ≤ 3 at week 12 (as observed analysis) was achieved by 95.9% of patients. The static Physician's Global Assessment (sPGA) success (defined as clear = 0 and almost clear = 1) at week 52 was achieved by 92.1% of patients. PASI 75, PASI 90, and PASI 100 were achieved by 98.0%, 87.8%, and 75.5% of patients, respectively, after approximately 52 weeks of treatment. The study also recorded very positive results concerning patient-reported outcomes. CONCLUSIONS: LIBERO-CZ confirms the fast onset and high clearance rates of brodalumab in real life in both biologic-naïve and biologic-experienced patients.

Department of Dermatology Faculty of Medicine University Hospital Ostrava Ostrava Czech Republic

Department of Dermatovenereology 1st Faculty of Medicine and General University Hospital Charles University Prague Czech Republic

Department of Dermatovenereology 3rd Faculty of Medicine Charles University and Královské Vinohrady University Hospital Prague Czech Republic

Department of Dermatovenereology Faculty of Medicine and University Hospital Charles University Pilsen Czech Republic

Department of Dermatovenereology Motol University Hospital Prague Czech Republic

Department of Dermatovenereology St Anne's University Hospital Faculty of Medicine Masaryk University Brno Brno Czech Republic

LEO Pharma Prague Czech Republic

Sanatorium of Professor Arenberger Prague Czech Republic

Zobrazit více v PubMed

Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. doi: 10.1136/bmj.m1590. PubMed DOI PMC

Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333–337. doi: 10.1111/jdv.12106. PubMed DOI

Douroudis K, Kingo K, Traks T, et al. Polymorphisms in the ATG16L1 gene are associated with psoriasis vulgaris. Acta Derm Venereol. 2012;92(1):85–87. doi: 10.2340/00015555-1183. PubMed DOI

Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014 May;70(5):871-81.e1-30. 10.1016/j.jaad.2013.12.018. PubMed

Kim HJ, Lebwohl MG. Biologics and psoriasis: the beat goes on. Dermatol Clin. 2019;37(1):29–36. doi: 10.1016/j.det.2018.07.004. PubMed DOI

Beringer A, Noack M, Miossec P. IL-17 in chronic inflammation: from discovery to targeting. Trends Mol Med. 2016;22(3):230–241. doi: 10.1016/j.molmed.2016.01.001. PubMed DOI

Elder JT. Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes Immun. 2009;10(3):201–209. doi: 10.1038/gene.2009.11. PubMed DOI PMC

Ellinghaus E, Ellinghaus D, Stuart PE, et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet. 2010;42(11):991–995. doi: 10.1038/ng.689. PubMed DOI PMC

Li J, Li D, Tan Z. The expression of interleukin-17, interferon-gamma, and macrophage inflammatory protein-3 alpha mRNA in patients with psoriasis vulgaris. J Huazhong Univ Sci Technolog Med Sci. 2004;24(3):294–296. doi: 10.1007/BF02832018. PubMed DOI

Teunissen MB, Koomen CW, de Waal MR, Wierenga EA, Bos JD. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol. 1998;111(4):645–649. doi: 10.1046/j.1523-1747.1998.00347.x. PubMed DOI

Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128(5):1207–1211. doi: 10.1038/sj.jid.5701213. PubMed DOI

Johnston A, Fritz Y, Dawes SM, et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol. 2013;190(5):2252–2262. doi: 10.4049/jimmunol.1201505. PubMed DOI PMC

Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008;159(5):1092–1102. doi: 10.1111/j.1365-2133.2008.08769.x. PubMed DOI PMC

Ramirez-Carrozzi V, Sambandam A, Luis E, et al. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol. 2011;12(12):1159–1166. doi: 10.1038/ni.2156. PubMed DOI

Campa M, Mansouri B, Warren R, Menter A. A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Ther (Heidelb) 2016;6(1):1–12. doi: 10.1007/s13555-015-0092-3. PubMed DOI PMC

Coimbra S, Figueiredo A, Santos-Silva A. Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis. Core Evid. 2014;21(9):89–97. doi: 10.2147/CE.S33940. PubMed DOI PMC

Russell CB, Rand H, Bigler J, et al. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody. J Immunol. 2014;192(8):3828–3836. doi: 10.4049/jimmunol.1301737. PubMed DOI

Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–286. doi: 10.1111/bjd.14493. PubMed DOI

Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328. doi: 10.1056/NEJMoa1503824. PubMed DOI

Gordon KB, Kimball AB, Chau D, et al. Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. Br J Dermatol. 2014;170(3):705–715. doi: 10.1111/bjd.12636. PubMed DOI PMC

Attia A, Abushouk AI, Ahmed H, et al. Safety and efficacy of brodalumab for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. Clin Drug Investig. 2017;37(5):439–451. doi: 10.1007/s40261-017-0500-9. PubMed DOI

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi: 10.1111/j.1365-2230.1994.tb01167.x. PubMed DOI

Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321–326. PubMed

Feuerhahn J, Blome C, Radtke M, Augustin M. Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis. Arch Dermatol Res. 2012;304(6):433–441. doi: 10.1007/s00403-012-1256-y. PubMed DOI

Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;27(7):36. doi: 10.1186/1477-7525-7-36. PubMed DOI PMC

Cetkovska P, Kojanova M, Arenberger P, Fabianova J. Současný stav moderní léčby psoriázy – aktualizovaná doporučení ČDS JEP k cílené léčbě závažné chronické psoriázy. Čes-slov Derm. 2019;94(4):135–164.

European Commission, Union Register of medicinal products for human use, Kyntheum® (brodalumab). http://ec.europa.eu/health/documents/community-register/html/h1155.htm. Accessed Sep 2023.

Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172(1):244–252. doi: 10.1111/bjd.13343. PubMed DOI

Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) J Invest Dermatol. 2015;135(11):2632–2640. doi: 10.1038/jid.2015.208. PubMed DOI

Belinchón I, Ramos JM, Carretero G, et al. Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm. J Eur Acad Dermatol Venereol. 2017;31(10):1700–1708. doi: 10.1111/jdv.14314. PubMed DOI

Pogácsás L, Borsi A, Takács P, et al. Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary. J Dermatolog Treat. 2017;28(7):635–641. doi: 10.1080/09546634.2017.1329504. PubMed DOI

Reich K, Mrowietz U, Radtke MA, et al. Drug safety of systemic treatments for psoriasis: results from the German Psoriasis Registry PsoBest. Arch Dermatol Res. 2015;307(10):875–883. doi: 10.1007/s00403-015-1593-8. PubMed DOI PMC

Strober B, Karki C, Mason M, et al. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry. J Am Acad Dermatol. 2018;78(2):323–332. doi: 10.1016/j.jaad.2017.10.012. PubMed DOI

Kojanova M, Fialova J, Cetkovska P, et al. Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries. Int J Dermatol. 2017;56(4):428–434. doi: 10.1111/ijd.13543. PubMed DOI

Maza A, Richard MA, Aubin F, et al. Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France. Br J Dermatol. 2012;167(3):643–648. doi: 10.1111/j.1365-2133.2012.10991.x. PubMed DOI

Kojanova M, Fialova J, Cetkovska P, et al. Demographic data, comorbidities, quality of life, and survival probability of biologic therapy associated with sex-specific differences in psoriasis in the Czech Republic. Dermatol Ther. 2021;34(2):e14849. doi: 10.1111/dth.14849. PubMed DOI

Adenubiova E, Arenberger P, Gkalpakioti P, et al. Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic. J Dermatolog Treat. 2018;29(6):579–582. doi: 10.1080/09546634.2018.1425358. PubMed DOI

Gargiulo L, Ibba L, Malagoli P, et al. Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis) Front Med (Lausanne) 2023;3(10):1196966. doi: 10.3389/fmed.2023.1196966. PubMed DOI PMC

Galan-Gutierrez M, Font-Ugalde P, Padilla L, et al. Brodalumab: efficacy, safety, and survival in mid-term (52 weeks) on real clinical practice in Andalucia. Spain Int J Dermatol. 2023;62(5):700–706. doi: 10.1111/ijd.16527. PubMed DOI

Papadavid E, Zafeiriou E, Georgiou S, et al. Real-world clinical outcomes of treatment with brodalumab in patients with moderate-to-severe psoriasis: a retrospective, 24-month experience from four academic dermatology centers in Greece. J Dermatolog Treat. 2022;33(7):3053–3059. doi: 10.1080/09546634.2022.2110836. PubMed DOI

Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31(2):213–220. doi: 10.1111/jdv.14007. PubMed DOI

Strober B, Papp KA, Lebwohl M, et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016;75(1):77–82.e7. doi: 10.1016/j.jaad.2016.03.026. PubMed DOI

Takeshita J, Callis Duffin K, Shin DB, et al. Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. J Am Acad Dermatol. 2014;71(4):633–641. doi: 10.1016/j.jaad.2014.05.001. PubMed DOI PMC

Rigopoulos D, Angelakopoulos C, Apalla Z, et al. Real world experience of brodalumab treatment in patients with moderate-to-severe plaque psoriasis in the Greek population: results from an interim analysis of the BrIDGE study. Dermatol Ther. 2022;35(12):e15886. doi: 10.1111/dth.15886. PubMed DOI

Imafuku S, Ohata C, Okubo Y, et al. Effectiveness of brodalumab in achieving treatment satisfaction for patients with plaque psoriasis: the ProLOGUE study. J Dermatol Sci. 2022;105(3):176–184. doi: 10.1016/j.jdermsci.2022.02.007. PubMed DOI